Bio­gen re­veals plans for con­fir­ma­to­ry Aduhelm study, promis­ing re­sults in 5 years

For the first time, Bio­gen re­leased de­tails Thurs­day on how it in­tends to prove that its by turns cel­e­brat­ed and ma­ligned drug Aduhelm can ac­tu­al­ly slow the de­cline of pa­tients with Alzheimer’s, as re­quired by the FDA.

The biotech said it will launch a glob­al 1,300-per­son tri­al next May that will ran­dom­ize ear­ly-stage Alzheimer’s pa­tients to re­ceive ei­ther Aduhelm or place­bo. It will prob­a­bly take about four years for the tri­al to gen­er­ate re­sults, the com­pa­ny said, push­ing a fi­nal an­swer to 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER